Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
80 shown of 9,054 total abstracts
  1. Abstract LBA4000LBA2026-04-02 · 19:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-396
    C. Saura, N. Rizvi · Cleveland Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract LBA4001LBA2026-04-04 · 18:45 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-648
    T. Mok, M.C. Garassino, H. Rugo · Johns Hopkins Kimmel Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract LBA4002LBA2026-04-04 · 15:45 CT · Arie Crown Theater
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    N. Rizvi, S. Antonia, L. Paz-Ares · Princess Margaret Cancer Centre
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract LBA4003LBA2026-04-01 · 21:15 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    J. Brahmer, M. Krop, C. Saura · Royal Marsden Hospital
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract LBA4004LBA2026-04-05 · 18:15 CT · S406
    PACIFIC-638: Imfinzi (durvalumab) 3L+ in NSCLC
    N. Rizvi, G. Curigliano · Institut Gustave Roussy
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract LBA4005LBA2026-04-05 · 14:15 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-389
    R. Herbst, M. Krop · Institut Gustave Roussy
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract LBA4006LBA2026-04-05 · 20:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-941 study)
    T. Mok, H. Borghaei, F. Andre · Vall d'Hebron Institute of Oncology
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract LBA4007LBA2026-04-04 · 14:15 CT · S406
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-318 study)
    T. Mok, R. Herbst, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Plenary SessionGastrointestinal Cancer📄🖼️
  9. Abstract LBA4008LBA2026-04-05 · 16:00 CT · Hall B1
    Quality of life outcomes with Tagrisso in patients with NSCLC
    G. Curigliano, J. Cortes · Massachusetts General Hospital
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract LBA4009LBA2026-04-03 · 16:00 CT · Hall B1
    Long-term follow-up of Lynparza 2L for prostate: OlympiA-57
    J. Cortes, H. Borghaei, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionGenitourinary Cancer—Prostate📄🖼️
  11. Abstract LBA4010LBA2026-04-03 · 14:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-860 study)
    S. Modi, E. Winer, H. Borghaei, et al. · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract LBA4011LBA2026-04-02 · 19:00 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with NSCLC
    F. Andre, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract LBA4012LBA2026-04-03 · 18:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-874
    S. Antonia, M.C. Garassino, G. Curigliano · Institut Gustave Roussy
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract LBA4013LBA2026-04-04 · 20:00 CT · E450
    Quality of life outcomes with Imfinzi in patients with NSCLC
    H. Rugo, T. Mok, S. Antonia, et al. · Dana-Farber Cancer Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract LBA4014LBA2026-04-02 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-957 study)
    E. Winer, S. Antonia, S. Peters · Johns Hopkins Kimmel Cancer Center
    Plenary SessionGynecologic Cancer📄🖼️
  16. Abstract LBA4015LBA2026-04-05 · 16:30 CT · E450
    Quality of life outcomes with Trodelvy in patients with TNBC
    S. Modi, S. Antonia, J. Brahmer, et al. · Karolinska Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract LBA4016LBA2026-04-03 · 15:30 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-309
    J. Brahmer, H. Rugo, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract LBA4017LBA2026-04-01 · 21:00 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    L. Paz-Ares, S. Modi, E. Winer, et al. · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract LBA4018LBA2026-04-01 · 19:00 CT · E450
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-975 study)
    C. Saura, L. Paz-Ares, S. Modi, et al. · Cleveland Clinic
    Plenary SessionGynecologic Cancer📄🖼️
  20. Abstract LBA4019LBA2026-04-04 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-692 study)
    S. Tolaney, C. Saura, R. Herbst, et al. · Dana-Farber Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract LBA4020LBA2026-04-03 · 14:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-665 study)
    L. Paz-Ares, S. Antonia, J. Brahmer · Karolinska Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract LBA4021LBA2026-04-05 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-802 study)
    M. Reck, H. Rugo, C. Robert, et al. · Princess Margaret Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract LBA4022LBA2026-04-03 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-683 study)
    S. Tolaney, S. Antonia, C. Saura · Peter MacCallum Cancer Centre
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  24. Abstract LBA4023LBA2026-04-05 · 20:15 CT · S100A
    IMpower-769: Tecentriq (atezolizumab) adjuvant in TNBC
    L. Paz-Ares, M. Reck, S. Modi · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract LBA4024LBA2026-04-01 · 19:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-340 study)
    S. Antonia, E. Winer, C. Robert, et al. · National Cancer Center Japan
    Plenary SessionGastrointestinal Cancer📄🖼️
  26. Abstract LBA4025LBA2026-04-04 · 19:00 CT · S100A
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-903
    A. Spira, M. Krop, C. Saura · Royal Marsden Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract LBA4026LBA2026-04-05 · 19:45 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Peters, C. Robert, S. Modi, et al. · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  28. Abstract LBA4027LBA2026-04-03 · 18:45 CT · S406
    Long-term follow-up of Lynparza neoadjuvant for ovarian: OlympiA-896
    S. Tolaney, C. Robert, M. Reck · Memorial Sloan Kettering Cancer Center
    Plenary SessionGynecologic Cancer📄🖼️
  29. Abstract LBA4028LBA2026-04-03 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-759 study)
    C. Saura, M.C. Garassino · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract LBA4029LBA2026-04-05 · 21:15 CT · Arie Crown Theater
    EV-802: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    A. Spira, S. Tolaney · Peter MacCallum Cancer Centre
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  31. Abstract LBA4030LBA2026-04-02 · 16:45 CT · S406
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    M.C. Garassino, E. Winer, P. Schmid · Vall d'Hebron Institute of Oncology
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract LBA4031LBA2026-04-04 · 15:30 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-129
    H. Borghaei, J. Brahmer, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract LBA4032LBA2026-04-03 · 21:15 CT · S100A
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-744
    J. Cortes, M. Krop · Royal Marsden Hospital
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract LBA4033LBA2026-04-04 · 15:30 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M. Reck, S. Antonia, R. Herbst, et al. · University of Chicago
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract LBA4034LBA2026-04-02 · 21:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-961 study)
    F. Andre, E. Winer, L. Paz-Ares · University of Chicago
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract LBA4035LBA2026-04-04 · 21:00 CT · S406
    IMpower-852: Tecentriq (atezolizumab) 1L in TNBC
    A. Spira, P. Schmid · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract LBA4036LBA2026-04-04 · 19:30 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    A. Spira, J. Brahmer, T. Mok, et al. · Institut Gustave Roussy
    Plenary SessionGastrointestinal Cancer📄🖼️
  38. Abstract LBA4037LBA2026-04-01 · 14:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-969
    H. Rugo, G. Curigliano, M.C. Garassino · MD Anderson Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract LBA4038LBA2026-04-02 · 16:00 CT · S100A
    FLAURA-439: Tagrisso (osimertinib) maintenance in NSCLC
    J. Brahmer, M. Krop, J. Cortes · Mayo Clinic
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract LBA4039LBA2026-04-01 · 19:00 CT · S406
    PACIFIC-584: Imfinzi (durvalumab) maintenance in biliary tract
    H. Borghaei, N. Rizvi, C. Saura, et al. · Massachusetts General Hospital
    Plenary SessionGastrointestinal Cancer📄🖼️
  41. Abstract LBA4040LBA2026-04-05 · 13:30 CT · E450
    Long-term follow-up of Lynparza neoadjuvant for ovarian: OlympiA-351
    R. Herbst, S. Tolaney, A. Spira, et al. · Stanford Cancer Institute
    Plenary SessionGynecologic Cancer📄🖼️
  42. Abstract LBA4041LBA2026-04-02 · 21:00 CT · Hall B1
    PALOMA-987: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    E. Winer, S. Antonia, S. Tolaney, et al. · Mayo Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract LBA4042LBA2026-04-02 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-670 study)
    E. Winer, C. Saura, J. Cortes · Vall d'Hebron Institute of Oncology
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract LBA4043LBA2026-04-02 · 15:15 CT · E450
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    S. Peters, N. Rizvi, T. Mok · MD Anderson Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract LBA4044LBA2026-04-01 · 19:45 CT · Arie Crown Theater
    EV-575: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    M. Krop, S. Modi, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  46. Abstract LBA4045LBA2026-04-04 · 14:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-400
    T. Mok, L. Paz-Ares, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract LBA4046LBA2026-04-01 · 20:45 CT · S100A
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-62
    G. Curigliano, F. Andre, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract LBA4047LBA2026-04-02 · 19:15 CT · S100A
    Quality of life outcomes with Lynparza in patients with prostate
    C. Robert, C. Saura, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionGenitourinary Cancer—Prostate📄🖼️
  49. Abstract LBA4048LBA2026-04-05 · 18:30 CT · Arie Crown Theater
    IMpower-409: Tecentriq (atezolizumab) 2L in TNBC
    J. Brahmer, A. Spira, R. Herbst, et al. · MD Anderson Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract LBA4049LBA2026-04-03 · 18:00 CT · S100A
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-533
    S. Tolaney, M. Krop, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  51. Abstract LBA4050LBA2026-04-05 · 18:00 CT · S406
    FLAURA-319: Tagrisso (osimertinib) maintenance in NSCLC
    F. Andre, M. Reck, C. Robert, et al. · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract LBA4051LBA2026-04-05 · 16:00 CT · S406
    Biomarker subgroup analysis of Opdivo in HCC (the CheckMate-188 study)
    J. Cortes, M. Reck · Chinese University of Hong Kong
    Plenary SessionGastrointestinal Cancer📄🖼️
  53. Abstract LBA4052LBA2026-04-03 · 19:45 CT · S100A
    CheckMate-733: Opdivo (nivolumab) neoadjuvant in NSCLC
    F. Andre, N. Rizvi, R. Herbst · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  54. Abstract LBA4053LBA2026-04-02 · 15:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-513
    T. Mok, M. Krop, S. Peters, et al. · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  55. Abstract LBA4054LBA2026-04-02 · 15:30 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-645
    G. Curigliano, S. Antonia · National Cancer Center Japan
    Plenary SessionGenitourinary Cancer—Prostate📄🖼️
  56. Abstract LBA4055LBA2026-04-05 · 20:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-998
    M. Krop, N. Rizvi, S. Antonia · National Cancer Center Japan
    Plenary SessionGastrointestinal Cancer📄🖼️
  57. Abstract LBA4056LBA2026-04-04 · 14:00 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in HCC
    N. Rizvi, F. Andre, G. Curigliano, et al. · Chinese University of Hong Kong
    Plenary SessionGastrointestinal Cancer📄🖼️
  58. Abstract LBA4057LBA2026-04-04 · 15:30 CT · E450
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-924 study)
    A. Spira, J. Brahmer, T. Mok, et al. · National Cancer Center Japan
    Plenary SessionLung Cancer—Small Cell📄🖼️
  59. Abstract LBA4058LBA2026-04-02 · 14:30 CT · Hall B1
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    C. Saura, M. Krop, N. Rizvi, et al. · Vall d'Hebron Institute of Oncology
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  60. Abstract LBA4059LBA2026-04-05 · 18:45 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    F. Andre, L. Paz-Ares, S. Antonia, et al. · Mayo Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract LBA4060LBA2026-04-02 · 16:30 CT · E450
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-783 study)
    J. Cortes, J. Brahmer, L. Paz-Ares, et al. · University of Chicago
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  62. Abstract LBA4061LBA2026-04-01 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-995 study)
    E. Winer, J. Cortes, C. Saura · National Cancer Center Japan
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  63. Abstract LBA4062LBA2026-04-04 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-327
    A. Spira, C. Robert · Royal Marsden Hospital
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract LBA4063LBA2026-04-03 · 15:15 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    F. Andre, A. Spira · Cleveland Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract LBA4064LBA2026-04-04 · 15:00 CT · S406
    MONARCH-829: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    M. Krop, H. Rugo, R. Herbst · Vall d'Hebron Institute of Oncology
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract LBA4065LBA2026-04-05 · 14:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-593
    M. Krop, T. Mok · MD Anderson Cancer Center
    Plenary SessionGastrointestinal Cancer📄🖼️
  67. Abstract LBA4066LBA2026-04-02 · 15:30 CT · Hall B1
    Long-term follow-up of Lynparza neoadjuvant for prostate: OlympiA-621
    S. Modi, A. Spira, J. Cortes, et al. · Massachusetts General Hospital
    Plenary SessionGenitourinary Cancer—Prostate📄🖼️
  68. Abstract LBA4067LBA2026-04-02 · 13:15 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-811
    C. Robert, G. Curigliano, J. Cortes, et al. · Dana-Farber Cancer Institute
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  69. Abstract LBA4068LBA2026-04-04 · 13:15 CT · S406
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    J. Cortes, M. Krop, A. Spira, et al. · National Cancer Center Japan
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  70. Abstract LBA4069LBA2026-04-03 · 18:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-818
    S. Tolaney, P. Schmid, J. Brahmer, et al. · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  71. Abstract LBA4070LBA2026-04-01 · 16:15 CT · E450
    PACIFIC-462: Imfinzi (durvalumab) adjuvant in SCLC
    N. Rizvi, P. Schmid · Cleveland Clinic
    Plenary SessionLung Cancer—Small Cell📄🖼️
  72. Abstract LBA4071LBA2026-04-04 · 16:00 CT · S406
    FLAURA-644: Tagrisso (osimertinib) adjuvant in NSCLC
    H. Borghaei, G. Curigliano, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract LBA4072LBA2026-04-01 · 13:15 CT · S406
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-271
    E. Winer, A. Spira · Massachusetts General Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract LBA4073LBA2026-04-01 · 20:30 CT · E450
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    C. Saura, H. Borghaei, P. Schmid, et al. · University of Chicago
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  75. Abstract LBA4074LBA2026-04-02 · 18:00 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    S. Antonia, S. Tolaney, M. Krop, et al. · Princess Margaret Cancer Centre
    Plenary SessionMelanoma📄🖼️
  76. Abstract LBA4075LBA2026-04-01 · 19:15 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-283
    C. Saura, M. Krop, E. Winer · Dana-Farber Cancer Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  77. Abstract LBA4076LBA2026-04-02 · 21:00 CT · S100A
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-507 study)
    S. Antonia, A. Spira, M.C. Garassino, et al. · Chinese University of Hong Kong
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  78. Abstract LBA4077LBA2026-04-02 · 20:00 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-497
    M.C. Garassino, R. Herbst, C. Robert, et al. · Karolinska Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  79. Abstract LBA4078LBA2026-04-05 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-521
    M. Reck, S. Tolaney, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  80. Abstract LBA4079LBA2026-04-03 · 16:15 CT · S406
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-470 study)
    S. Modi, C. Saura, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionGastrointestinal Cancer📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.